Holen Sie sich die Stockscreener-App
7.795
4.43%
0.305
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt SLDB?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$7.49
Offen:
$7.5
24-Stunden-Volumen:
612.70K
Relative Volume:
0.47
Marktkapitalisierung:
$766.96M
Einnahmen:
$14.79M
Nettoeinkommen (Verlust:
$-174.33M
KGV:
-3.8553
EPS:
-2.0219
Netto-Cashflow:
$-157.44M
1W Leistung:
+20.52%
1M Leistung:
+15.88%
6M Leistung:
+42.74%
1J Leistung:
+151.10%
1-Tages-Spanne:
$7.35
$8.10
1-Wochen-Bereich:
$6.63
$8.10
52-Wochen-Spanne:
$2.41
$8.72
Solid Biosciences Inc Stock (SLDB) Company Profile
Firmenname
Solid Biosciences Inc
Sektor
Branche
Telefon
617-337-4680
Adresse
500 RUTHERFORD AVENUE, CHARLESTOWN, MA
Compare SLDB vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SLDB
Solid Biosciences Inc
|
7.795 | 736.95M | 14.79M | -174.33M | -157.44M | -2.0219 |
VRTX
Vertex Pharmaceuticals Inc
|
433.53 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.09 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
747.05 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.56 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.57 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Solid Biosciences Inc Stock (SLDB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-20 | Eingeleitet | Guggenheim | Buy |
| 2025-12-04 | Eingeleitet | Needham | Buy |
| 2025-06-26 | Eingeleitet | Citigroup | Buy |
| 2025-01-08 | Eingeleitet | Truist | Buy |
| 2024-12-13 | Eingeleitet | Wedbush | Outperform |
| 2024-12-10 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-07-15 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-06-24 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-05-31 | Fortgesetzt | Piper Sandler | Overweight |
| 2024-03-28 | Eingeleitet | William Blair | Outperform |
| 2024-03-15 | Eingeleitet | Citigroup | Buy |
| 2024-03-14 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-12-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-07-12 | Eingeleitet | Piper Sandler | Neutral |
| 2021-05-27 | Eingeleitet | Jefferies | Buy |
| 2021-03-16 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-03-09 | Eingeleitet | Barclays | Overweight |
| 2021-01-08 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2020-07-28 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-05-07 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-10-11 | Eingeleitet | Evercore ISI | Outperform |
| 2019-08-29 | Herabstufung | Citigroup | Neutral → Sell |
| 2019-08-19 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-08-16 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2019-05-14 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2019-05-14 | Herabstufung | Goldman | Neutral → Sell |
| 2019-02-08 | Hochstufung | Citigroup | Sell → Neutral |
| 2019-02-08 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2018-11-06 | Eingeleitet | Citigroup | Sell |
| 2018-09-06 | Eingeleitet | Credit Suisse | Neutral |
Alle ansehen
Solid Biosciences Inc Aktie (SLDB) Neueste Nachrichten
Solid Biosciences (NASDAQ:SLDB) Trading 6.4% HigherHere's What Happened - MarketBeat
SLDB PE Ratio & Valuation, Is SLDB Overvalued - Intellectia AI
Solid Biosciences Stock: Gene Therapy Pipeline and Strategic Position in Neuromuscular Disorders - AD HOC NEWS
Director at Solid Biosciences (NASDAQ: SLDB) exercises RSUs - Stock Titan
SLDB Stock Price, Quote & Chart | SOLID BIOSCIENCES INC (NASDAQ:SLDB) - ChartMill
[EFFECT] Solid Biosciences Inc. SEC Filing - Stock Titan
Big Picture: Whats the beta of Solid Biosciences Inc stockMarket Growth Review & Real-Time Buy Signal Notifications - baoquankhu1.vn
Solid Biosciences (NASDAQ:SLDB) Trading Down 6.7%Here's Why - MarketBeat
Solid Bio wins new buy at Guggenheim on lead asset - MSN
Aug Analyst Calls: Is Solid Biosciences Inc part of any ETF2026 Highlights & High Accuracy Investment Signals - baoquankhu1.vn
Solid Biosciences (NASDAQ:SLDB) Shares Up 5.5% After Analyst Upgrade - MarketBeat
Truist Financial Upgrades Solid Biosciences (NASDAQ:SLDB) to "Strong-Buy" - MarketBeat
JPMorgan Chase & Co. Raises Solid Biosciences (NASDAQ:SLDB) Price Target to $12.00 - MarketBeat
SLDB: JP Morgan Raises Price Target to $12 with Overweight Ratin - gurufocus.com
HC Wainwright Expects Higher Earnings for Solid Biosciences - MarketBeat
Solid Biosciences (NASDAQ:SLDB) Earns "Buy" Rating from HC Wainwright - MarketBeat
H.C. Wainwright Maintains Solid Biosciences(SLDB.US) With Buy Rating, Maintains Target Price $20 - Moomoo
SLDB: HC Wainwright & Co. Reiterates Buy Rating with $20 Target - GuruFocus
Solid Biosciences Inc. (NASDAQ:SLDB) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Solid Biosciences Faces Pricing Challenges Amid Changing Gene Therapy Economics Due to Updated Regulations - Bitget
Guggenheim initiates coverage of Solid Biosciences (SLDB) with buy recommendation - MSN
Evolving Tax Rules and New Excise Levies Threaten Solid Biosciences’ Profitability and Cash Flows - TipRanks
RA CAPITAL MANAGEMENT, L.P. Reduces Stake in Solid Biosciences Inc - GuruFocus
Guggenheim Initiates Coverage on Solid Biosciences (SLDB) with B - gurufocus.com
Will Solid Biosciences Inc stock recover after earnings2026 Key Lessons & Weekly Watchlist for Consistent Profits - baoquankhu1.vn
Solid Biosciences (NASDAQ:SLDB) Shares Gap UpWhat's Next? - MarketBeat
Solid Bio stock wins new Buy at Guggenheim (SLDB:NASDAQ) - Seeking Alpha
SLDB: Guggenheim Initiates Coverage with a 'Buy' Rating at $26 | - GuruFocus
Guggenheim Initiates Coverage on Solid Biosciences (NASDAQ:SLDB) - MarketBeat
Solid Biosciences (NASDAQ:SLDB) Earns "Buy" Rating from Chardan Capital - MarketBeat
Solid Biosciences (SLDB) Receives Maintained 'Buy' Rating from C - GuruFocus
Solid Biosciences (NASDAQ:SLDB) Given "Buy" Rating at Needham & Company LLC - MarketBeat
Solid Biosciences (SLDB) Receives Buy Rating and Positive Outloo - GuruFocus
Guggenheim Initiates Solid Biosciences at Buy With $26 Price Target - marketscreener.com
SLDB: Needham Reiterates 'Buy' Rating with Price Target of $19.0 - GuruFocus
Solid Biosciences Inc. 2025 Annual Report: Advancing Gene Therapy for Neuromuscular and Cardiac Diseases - Minichart
Solid Biosciences (NASDAQ:SLDB) Posts Earnings Results, Beats Estimates By $0.01 EPS - MarketBeat
Solid Biosciences (SLDB) Strengthens Financial Position with Inc - gurufocus.com
Solid Biosciences (NASDAQ: SLDB) resale registration for 42.8M shares - Stock Titan
[S-3] Solid Biosciences Inc. Shelf Registration Statement | SLDB SEC FilingForm S-3 - Stock Titan
Solid Biosciences Reports Positive Interim Data for SGT-003 and Advances Clinical Programs in Duchenne Muscular Dystrophy, Friedreich’s Ataxia, and CPVT - Quiver Quantitative
Solid Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates - GlobeNewswire
Solid targets Phase 3 Duchenne dosing in April after positive data - Stock Titan
Gene therapy pipeline at Solid Biosciences (NASDAQ: SLDB) targets Duchenne and cardiac disease - Stock Titan
Solid Biosciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Solid Biosciences Inc. spotlights leadership role in Friedreich ataxia research collaboration - Traders Union
According to the latest disclosure documents from the U.S. Securities and Exchange Commission, biotechnology company Solid Biosciences has submitted a resale prospectus, and a certain shareholder of the company plans to resell up to 1.3 million shares o - Bitget
Geopolitics Watch: What analysts say about Solid Biosciences Inc stockWeekly Trade Review & Reliable Entry Point Alerts - baoquankhu1.vn
PERCEPTIVE ADVISORS LLC Increases Stake in Solid Biosciences Inc - GuruFocus
RA Capital boosts Solid Biosciences (SLDB) ownership to 9.9% with March buys - Stock Titan
H.C. Wainwright Reaffirms Their Buy Rating on Solid Biosciences (SLDB) - The Globe and Mail
Finanzdaten der Solid Biosciences Inc-Aktie (SLDB)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.90%
1.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):